Personalized Oncology

Tempus Uses AI and Big Data for Precision Medicine

When you’ve been writing about technology for as long as we have at Nanalyze you start to see patterns emerge. One of the most interesting – and potentially biggest game-changers in the life sciences arena – is the emergence of precision medicine. The approach takes into account individual variability in genes, among other factors, to […]

Biodesix – A Lung Cancer Diagnostics Stock

One can’t help but wonder why the Americans are so worried about peanut allergies when 34 million of them use a product every day that slowly kills them. In the United States, cigarette smoking is linked to about 80% to 90% of lung cancer deaths. While we may not be able to pry someone’s cigarettes from their […]

A Liquid Biopsy Stock That’s Going Places

The so-called “cure for cancer” isn’t one magical treatment that may or may not be secretly hidden from everyone as part of a vast conspiracy by big pharma. Today’s spray-and-pray approach to cancer treatment has varying degrees of success targeting the over 200 types of cancer, each instance of which is unique to the patient. […]

6 CRISPR Applications from Healthcare Startups

One question we’re often asked at Nanalyze is what emerging technology do we think will be most disruptive in the long term. The short answer: All of them. Otherwise, we wouldn’t be devoting long hours at the laptop between trips to the local dispensary writing about all of this amazing progress. Artificial intelligence, as we’ve […]

Flatiron: Big Data from Cancer Centers in the Cloud

Cancer isn’t something we like talking about, maybe because it is the cause of one of every four deaths in the United States, and nobody likes talking about death. Almost everyone knows someone who has been affected by cancer, and we all like to throw around the term “a cure for cancer”. The fictional “cure for cancer” […]

Personalized Oncology IPO Epizyme

In earlier articles, we discussed several companies involved in personalizing oncology drugs including Foundation Medicine and Champions Oncology. With plans to personalize therapeutics for genetically defined cancers, one recent IPO, Epizyme, is at the forefront of this growing trend. Business Focus Founded in 2007, Epizyme has taken advantage of sequencing of the human genome by developing […]

A TINY gamble on Champions Oncology

In a previous article we discussed the SEC warning against investing in companies that conduct a reverse merger on the over-the-counter exchange.  However, there are always exceptions to any rule. In looking at Harris and Harris Group’s (NASDAQ:TINY) latest 10-Q we see that TINY has a current investment in an OTC stock called Champions Oncology (OTCMKTS:CSBR). […]

6 things to like about Foundation Medicine’s Proposed IPO

In an earlier article we discussed the June IPO of Nanostring, an oncology company using microfluidics to test for the risk of recurrence for breast cancer. Another interesting oncology company that filed for IPO on July 29th 2013 is Foundation Medicine. About Foundation Medicine Foundation Medicine is involved in cancer genomics, that is examining the genetic […]